Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2686 to 2700 of 9102 results

  1. Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment

    In development Reference number: GID-HTG10865 Expected publication date:  15 September 2026

    HealthTech guidance
    In development

  2. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 5 August 2026.

    Technology appraisal guidance
    In consultation

  3. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-HTG10870 Expected publication date:  15 October 2026

    HealthTech guidance
    In development

  5. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 7 July 2026.

    In consultation

  6. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 3 July 2026.

    In consultation

  7. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. In-situ abdominal normothermic regional perfusion to preserve donor livers during retrieval for transplantation after controlled circulatory death: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 28 July 2026.

    In consultation

  10. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders

    In development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

    In development Reference number: GID-TA11669 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  12. In-situ abdominal normothermic regional perfusion to preserve donor livers during retrieval for transplantation after controlled circulatory death

    In development Reference number: GID-HTG10880 Expected publication date:  19 November 2026

    HealthTech guidance
    In development

  13. Headaches (update): Prophylactic treatment of migraine - Candesartan: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 21 July 2026.

    NICE guideline
    In consultation

  14. Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease

    Awaiting development Reference number: GID-TA12460 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Asciminib for untreated Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase

    Awaiting development Reference number: GID-TA12455 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development